The association between genetic variations of vascular endothelial growth factor (VEGF) gene and the risk for atherosclerosis has been hypothesized. We aimed to assess the relationship between rs2010963 (+405 C/G) polymorphism and presence, severity, and outcome of coronary artery disease (CAD) in an Iranian cohort.
October 2009. In this study, the first data gathering among a cohort of 484 participants (93% of study subjects) was performed successfully by the physicians during the 5-year follow-up period (i.e., from the dates of coronary angiography until October 31, 2014) and events including cardiovascular mortality, myocardial infarction, and restenosis were recorded.
To precisely evaluate the severity of CAD in the subjects, both Gensini score (GS) was calculated by cardiologists grading narrowing of the epicardial coronary artery and reduction in the lumen diameter. 25 The number of involved coronary vessels was also determined.
Coronary artery stenosis with more than 50% luminal narrowing was regarded as CAD-positive condition. 26 Baseline information, including gender, age, as well as history of diabetes, hypertension, and cigarette smoking, was collected by interviewing the participants or reviewing their historical medical records. Individuals with blood pressure ≥140/90 mm Hg and/or history of antihypertensive drug consumption were considered hypertensives. 27 According to the American Diabetes Association (ADA) definition, diabetes mellitus was defined as the use of insulin or a hypoglycemic agent, a fasting plasma glucose level of 126 mg/dL or more, or a 2-hour post-load plasma glucose level of 200 mg/dL or more. 26 Patients with cardiovascular diseases (except for CAD), renal insufficiency, arthritis, gastrointestinal disorders, and malignancies were excluded from this study. The research protocol was approved by the institutional ethics committee at the Tehran Heart Center, and the participants signed informed consents.
| Laboratory measurements, extraction of genomic DNA, and single nucleotide polymorphism genotyping
The concentrations of serum glucose, cholesterol, triglyceride, and high-density lipoprotein cholesterol of all the blood samples collected from the subjects following a 12-to 14-hour fast, were measured. The
Friedewald equation was used to calculate the concentration of lowdensity lipoprotein cholesterol. 28 DNA samples were obtained from 10 mL of blood via a standard salting-out method. 29 The quality of the extracted DNA was evaluated via the spectrophotometric method and calculation of the optical density ratio (A 260 /A 280 ). 30 Genotypes were determined using the TaqMan real-time PCR technique on RotorGene 6000 (Corbett Life Science Inc., Sydney, Australia) and an allelic discrimination assay kit (ABI; Applied Biosystems Inc., California, USA).
| Statistical analysis
SPSS software version 18 (SPSS Inc., Chicago, USA) was employed as a statistical package in the analysis and comparison of the variables between the two groups. The continuous variables were analyzed using Student's t test or non-parametric Mann-Whitney U test.
The categorical variables were analyzed using the chi-squared test or
Fisher's exact test if required. The genotype association between the two different groups was determined via the logistic regression analysis and odds ratio (OR) and 95% confidence interval (CI) for OR were also expressed. A P value <.05 was considered significant. The relative hazard ratio (HR) and 95%CI were determined for cardiovascular events using the COX proportional hazard analysis. According to the Hardy-Weinberg equilibrium law, the balance of the allele frequencies of the polymorphism was investigated. G power 3.1 software (Heinrich-Heine-Universität, Düsseldorf, Germany) was used to calculate the power of this study.
| RESULTS

| Laboratory findings and clinical characteristics
In this cohort study, a total of 520 subjects (353 males, 167 females; mean age=57.8±10.7 years for the males and 59.8±9.0 years for the females) were divided into two groups according to their angiography results: 347 patients with positive CAD and 173 with angiographically normal coronary arteries. In total, 484 of 520 individuals were followed up to assess Major Adverse Cardiovascular Events (MACE). Table 1 compares the demographic data and laboratory findings between the two groups with and without CAD. The majority of cardiovascular risk factors were more frequent in CAD group than those with normal coronary artery. In this regard, the frequencies of male gender, as well as the prevalence of smoking, hyperlipidemia, and diabetes mellitus were higher in the CAD group compared to non-CAD group. The mean age in CAD patients was also higher when compared to the normal controls (P=.001). However, the two groups were similar in family history of CAD, hypertension, and body mass index (BMI).
| Prevalence of +405 G/C gene polymorphism
The genotypic distribution in our study population agreed with the CAD, coronary artery disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. Data are presented as mean±SD or n (n %). No significant association was found between the heterozygote model (GC) of VEGF +405 C/G polymorphism and CAD risk (P=.175).
T A B L E 1 Comparing baseline characteristics between CAD and non-CAD groups
In addition, CC/CG genotype in C allele carriers greatly increased the susceptibility of CAD (P=.027).
Allelic analysis of the SNP after adjustment for covariates showed that the presence of C allele as the minor allele tended the subjects to have higher susceptibility to CAD in comparison with the G allele (OR=1.66, 95%CI=1.20-2.30; P=.002; Table 2 ).
In this study, the association between +405 C/G genotype distributions and CAD severity was evaluated by two scoring tools: the number of involved coronary vessels and Gensini score. The frequency of +405 C/G VEGF polymorphism in the patients with one, two, and three affected vessels and the mean of the GSs are presented in Table 3 .
The analysis of +405 C/G genotypes in these subgroups of CAD revealed that the distribution of the CC and GC genotypes and also C allele did not have a relationship with the rise in the number of the involved vessels and also with the increase in Gensini score.
In this study, the association between VEGF +405 C/G polymorphism and mortality due to CAD was investigated. Overall, 484
individuals from 520 study subjects were followed up for a median follow-up time of 64 months. revealed with increased risk of CAD-related death (Table 4) .
Analysis of allele frequencies data revealed that minor allele (C allele) of the polymorphism could be as a slight high-risk allele for cardiac death with hazard ratio 1.720 (P=.056). Regarding association between patients' survival and patterns of genotypes, the 5-year survival in C and G alleles subgroups were 92.3% and 94.3% in CAD group and 95.7% and 98.0% in non-CAD group, respectively ( Fig. 1 and Fig. 2 ).
T A B L E 3
The association between gene variants and CAD severity
rs2010963 (+405 C/G)
Vessel score (n (%)) P, P value (P significant <.05); P values were calculated by chi-squared test. SVD, single-vessel coronary artery disease, 2VD, two-vessel coronary artery disease; 3VD, three-vessel coronary artery disease. Grades of CAD severity were based on vessel score and Gensini score. Minor allele frequency in this study was calculated to be 0.23 for the normal group and 0.32 for the CAD group. The sample size of 520 individuals with a 2:1 case: control ratio made the statistical power of this study more than 90%. The overall genotyping error rate between the replicates was 1.7%.
T A B L E 4 The association between gene variants and CAD outcome rs2010963 (+405 C/G)
Cardiovascular events Hazard ratios of CV death
No events (n=308)
Restenosis
| DISCUSSION
This study investigated the correlation between VEGF rs2010963
(+405 C/G) polymorphism and the presence and severity of CAD and searched the potential interactions between this gene variation and risk of cardiovascular death. Our main findings showed that +405 C/G polymorphism is associated with the increased risk for CAD but not with CAD severity. To the best of our knowledge, this is the first study suggested that VEGF rs2010963 polymorphism could be related to worse survival among patients with CAD. According to our results on association between lower long-term survival and presence of C allele in both CAD and non-CAD groups, the role of this allele for predicting long-term lower survival in both groups is obvious.
Vascular endothelial growth factor has been known as a multifunctional glycoprotein in the endothelial signaling pathway which is involved in angiogenesis, monocyte activation and migration, as well as vascular smooth muscle cell migration. 6, 7 Although the role of VEGF in atherosclerotic changes remains ambiguous in the literature, most previous studies have reported that the role of VEGF in the progression of CAD could be link to angiogenesis and vasoactivation activity, proliferation of smooth muscles cells, pathways of coagulation, fibrinolysis and renin-angiotensin-aldosterone and inflammation factors. [21] [22] [23] [24] Some studies have also observed that VEGF acts as an endogenous In this study, the results for VEGF +405 C/G genotyping and allele frequencies were analyzed both before and after adjusting for hyperlipidemia, diabetes mellitus, age, and gender. Our data showed that the subjects carrying CC genotype and also those carrying C allele had a higher susceptibility to CAD, which pointed toward the potential role of VEGF in CAD development and clinical complications of atherosclerosis. In spite of this strong association, further analysis of the data in two CAD severity models showed no dose-dependent effect of the
The survival curve in non-coronary artery disease patients according to vascular endothelial growth factor genotyping polymorphism on the CAD severity (assessed by the Gensini score) and the degree of arterial obstruction (assessed by the number of involved coronary vessels) in our study population.
We drew on the Gensini score as a precise method for the assessment of CAD severity according to angiographic findings. The Gensini score calculation is based on the evaluation of the number of epicardial coronary artery segments with stenosis, reduction in the lumen diameter, and localization of stenotic changes. 25 In addition to the Gensini scoring system, we used vessel score model (based on the number of diseased coronaries) as a confirmatory analysis mode.
Although this study did not examine the possible association between the genotypes and expression of VEGF, there are some evidence implying that VEGF genotypes at sites of +405, −2578, and +936 may be related to the amounts of VEGF protein production. Previous studies have suggested that the presence of +405 C allele and −2578 A allele in the VEGF gene is associated with elevated VEGF levels and development of CAD, whereas a correlation has been observed between +936 T allele VEGF polymorphism and lower VEGF serum levels but not with the severity of CAD. [33] [34] [35] [36] The association between VEGF expression and susceptibility to atherosclerosis may imply that VEGF protein plays an important role in modulating atherosclerosis changes.
In this study, the results of a 5-year follow-up period demonstrated that VEGF and its genetic variations of rs2010963 could predict the mortality and survival of CAD patients. The high hazard ratios (more than 2 for genotypes and 1.73 for C allele) of death due to atherosclerotic changes among our SNP carriers indicated that VEGF +405 C/G polymorphism could be deemed a mortality risk factor in this atherosclerosis-related disease.
There are some limitations in our cohort study. Although our sample size provide power more than 90%, we only analyzed the +405 C/G polymorphism regardless of other polymorphisms related to susceptibility of CAD and its clinical outcomes. Moreover, the complete elimination of interaction between the use of drugs and genetic markers was impossible. Reviewing the literature shows that the presence of both polymorphisms is significantly associated with both CAD and myocardial ischemic events, however, the triggering role of +405 (G/C) SNP as a risk factor was shown to be higher than −2578 (C/A) to predict CAD.
As revealed by Lin et al. (2010) , the odds ratio for predicting significant CAD was higher than for +405 (G/C) SNP when compared to −2578 (C/A). In another survey by Lin et al. (2010) , there was a significant independent association of +405 C/G genotype with CAD and its diffuse score in the uni-and multivariate regression analysis, but no association was found between VEGF-2578C/A polymorphism and both atherosclerotic parameters. Because of stronger evidence on stimulatory role of +405 (G/C) SNP in CAD, we preferred to assess this polymorphism among our population.
| CONCLUSIONS
In conclusion, our cohort study suggested that VEGF +405C/G polymorphism could be considered as a genetic marker for predicting CAD in Iranian population without a causality effect on CAD severity. In addition, our study hinted this hypothesis that the risk of mortality due to CAD can be predicted by confirming +405 C/G VEGF genetic variations.
